Out of all the drug classes detailed in this review, the GLP-1 receptor agonists liraglutide and semaglutide, as well as tirzepatide, have proven to be efficient in the treatment of type II diabetes mellitus in addition to obesity, with beneficial effects on blood pressure observed in both situations. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.